Evidence map›Paper›PMID 42240482›Full record

ArticleBiochemistry2026

Structure-Activity Relationship Study of Antimicrobial Peptide with Cross-Kingdom Activity.

Aparna Palakkurussi Rathessan, Fereshteh Ghazisaeedi, Krithika Unmesh, Pascal-Kolja Bingül, Johannes Kupke, Suvrat Chowdhary, Dennis Hanke, Maria Andrea Mroginski, Marcus Fulde, Beate Koksch

Abstract read
In one paragraph

Article in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aparna Palakkurussi RathessanInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin 14195, Germany.ORCID 0009-0007-4690-117X
Fereshteh GhazisaeediInstitute of Microbiology and Epizootics, Center of Infection Medicine, Freie Universität Berlin, Berlin 14163, Germany.
Krithika UnmeshDepartment of Chemistry, Technische Universität Berlin, Berlin 10623, Germany.
Pascal-Kolja BingülSchool of Veterinary Medicine, Institute of Veterinary Anatomy, Freie Universität Berlin, Berlin 14195, Germany.
Johannes KupkeInstitute of Microbiology and Epizootics, Center of Infection Medicine, Freie Universität Berlin, Berlin 14163, Germany.ORCID 0000-0001-9045-9410
Suvrat ChowdharyInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin 14195, Germany.
Dennis HankeInstitute of Microbiology and Epizootics, Center of Infection Medicine, Freie Universität Berlin, Berlin 14163, Germany.
Maria Andrea MroginskiDepartment of Chemistry, Technische Universität Berlin, Berlin 10623, Germany.ORCID 0000-0002-7497-5631
Marcus FuldeInstitute of Microbiology and Epizootics, Center of Infection Medicine, Freie Universität Berlin, Berlin 14163, Germany.
Beate KokschInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin 14195, Germany.ORCID 0000-0002-9747-0740

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread emergence of antibiotic-resistant pathogens poses a significant global health challenge and underscores the need for novel approaches to accelerate antimicrobial discovery. Antimicrobial peptides (AMPs) have gained attention as promising candidates due to their broad-spectrum activity, including efficacy against multidrug-resistant bacterial strains. SAJO-2, an antimicrobial peptide developed by Sarojini and colleagues, features a tryptophan zipper-like motif incorporating a central d-Phe-2-Abz unit, where 2-Abz functions as a conformationally constrained β-turn-inducing peptidomimetic scaffold. Modification of SAJO-2 in prior joint work from our groups through differential fluorination enhanced its antimicrobial potency; however, it also increased susceptibility to enzymatic digestion by β-trypsin. To address this limitation, the current research focuses on improving the overall efficacy of SAJO-2 through the incorporation of D-amino acids, beta backbone modifications, and a bulky pentafluorinated amino acid residue. All modified peptides exhibit resistance to enzymatic degradation, while antimicrobial activity was retained to differing degrees across organisms.

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesAmino Acid SequenceMicrobial Sensitivity TestsStructure-Activity RelationshipAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptides

Identifiers

PMID42240482
PMCPMC13276844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.